Idorsia (IDRSF) Stock Price, News & Analysis

Company Overview

Idorsia Ltd. is a Swiss biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. Its research activities span areas including cardiovascular disease, central nervous system disorders, immunology and rare diseases. The company operates from its headquarters in Allschwil, Switzerland, and serves international pharmaceutical markets through its own commercial operations and collaboration arrangements.

Idorsia’s commercial portfolio includes QUVIVIQ (daridorexant), an orexin receptor antagonist used to treat insomnia in eligible adults, and PIVLAZ (clazosentan), a therapy intended to reduce the risk of cerebral vasospasm and related complications following aneurysmal subarachnoid hemorrhage. The company has also developed aprocitentan, marketed as TRYVIO in the United States for certain adults with treatment-resistant hypertension.

Idorsia was established in 2017 following the acquisition of Actelion by Johnson & Johnson, with Actelion’s discovery and early-stage research operations forming the foundation of the new company. Idorsia was founded by Jean-Paul Clozel and Martine Clozel and is led by Jean-Paul Clozel, who has served as chief executive officer. The company continues to advance a pipeline of internally discovered medicines alongside its marketed products.

Key Stats

• Today's Range: $4.95 to $4.95
• 50-Day Range: $4.95 to $7.25
• 52-Week Range: $3.50 to $8.19
• Volume: N/A
• Average Volume: 9,519 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:IDRSF
• CIK: N/A
• Web: www.idorsia.com
• Phone: (158) 844-0000
• Fax: N/A
• Employees: 487
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A